Response rates and recurrence patterns after low-dose radiotherapy with 4  Gy in patients with low-grade lymphomas

ConclusionPrimary LDRT is an effective treatment with high ORR and long-lasting remissions in a  subset of patients with low-grade lymphoma, and may therefore be a curative treatment option for patients with low tumor burden. LDRT with the CD20 antibody obinutuzumab will soon be tested in a prospective multicenter trial.
Source: Strahlentherapie und Onkologie - Category: Cancer & Oncology Source Type: research